Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090071 · ClinicalTrials.gov registry record · Phase 4
Trial Evaluating Both Tolerability and Improvement for Signs of Facial Photoaging, Discoloration, and Texture in Adult Females of All Skin Types by Combining a Placebo Moisturizer and Non-ablative Laser.
A Phase 4 study, sponsored by Austin Institute for Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT06090071: Completed Phase 4 study, sponsored by Austin Institute for Clinical Research.
NCT06090071 is a Phase 4 study that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 38 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090071, a Phase 4 study, has completed, sponsored by Austin Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a phase 4 trial evaluating the clinical effect of combining a placebo moisturizer and non-ablative laser to improve procedural outcomes in patients with facial dyschromia. This study's objective is to evaluate both the tolerability and improvement in signs of photoaging for a placebo moisturizer used in combination with a non-ablative laser. Physician assessments, patient reported outcomes, and digital photos will be captured.
Primary Outcome
Measured by Live Clinical Investigator Assessment including, Skin Clarity, Appearance of Pores, Skin Texture/Smoothness (Visual), Skin Texture/Smoothness (Tactile), Hyperpigmentation, Skin Tone Evenness, Radiance/Brightness and Overall Healthy Appearance of Skin/Overall Skin Quality, and Tolerance Evaluation. Local cutaneous tolerability will be evaluated by assessing the signs of erythema, dryness, and scaling and by subject reporting of the degree of burning, stinging, and itching. Local cutan
Interventions
- DEVICE LaseMD Laser
- DEVICE Sciton Laser
- DRUG Phyto A+ Brightening Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-11-14 |
| Est. Completion | 2024-09-05 |
| Phase | Phase 4 |
What the finished NCT06090071 record still lists
NCT06090071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which LaseMD Laser is the first listed.
NCT06090071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06090071 about?
NCT06090071 is a clinical study titled "Trial Evaluating Both Tolerability and Improvement for Signs of Facial Photoaging, Discoloration, and Texture in Adult Females of All Skin Types by Combining a Placebo Moisturizer and Non-ablative Laser.". This is a phase 4 trial evaluating the clinical effect of combining a placebo moisturizer and non-ablative laser to improve procedural outcomes in patients with facial dyschromia. This study's objective is to evaluate both the tolerability and improvement in signs of photoaging for a placebo moistur...
What is the current status of trial NCT06090071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2023-11-14. Estimated completion is 2024-09-05.
What interventions are being tested in trial NCT06090071?
The interventions under investigation include: LaseMD Laser (DEVICE), Sciton Laser (DEVICE), Phyto A+ Brightening Treatment (DRUG).
Who is sponsoring clinical trial NCT06090071?
This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06090071's enrollment target sits among peer trials
38 1476th of 2000 higher than 519 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI